{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T20:54:15Z","timestamp":1785876855788,"version":"3.56.0"},"reference-count":194,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Oncolytic viruses (OVs) are natural or recombinant viruses that can directly lyse tumor cells without damaging normal cells. They enhance anti-tumor immunity by releasing antigens and activating inflammatory responses within the tumor microenvironment (TME). This offers a new therapeutic approach for MPE and solid tumors. This review discusses the progress of OVs administered via intrapleural and intratumoral routes, emphasizing their potential in MPE treatment and the challenges posed by the complex intrapleural environment, which affects the direct interaction between OVs, tumor cells, and immune cells. This review also discusses the regulatory barriers, safety concerns and accessibility of oncolytic virus therapy.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1570698","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T05:23:09Z","timestamp":1745558589000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Oncolytic viruses: a promising therapy for malignant pleural effusion and solid tumors"],"prefix":"10.3389","volume":"16","author":[{"given":"Xinya","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binlei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/j.cell.2019.01.051","article-title":"SnapShot: cancer immunotherapy with oncolytic viruses","volume":"176","author":"Gujar","year":"2019","journal-title":"Cell"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2020.100639","article-title":"Oncolytic virotherapy: Challenges and solutions","volume":"45","author":"Goradel","year":"2021","journal-title":"Curr Problems Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.15089","article-title":"Targeting STAT3 enhances NDV-induced immunogenic cell death in prostate cancer cells","volume":"24","author":"Wang","year":"2020","journal-title":"J Cell Mol Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00436","article-title":"STAT3 contributes to oncolytic newcastle disease virus-induced immunogenic cell death in melanoma cells","volume":"9","author":"Shao","year":"2019","journal-title":"Front Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-12-2687","article-title":"Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans","volume":"73","author":"Breitbach","year":"2013","journal-title":"Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-15-2667","article-title":"Molecular pathways: mechanism of action for talimogene laherparepvec, a new oncolytic virus immunotherapy","volume":"22","author":"Kohlhapp","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13046-016-0353-8","article-title":"Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model","volume":"35","author":"El-Shemi","year":"2016","journal-title":"J Exp Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001486","article-title":"Clinical landscape of oncolytic virus research in 2020","volume":"8","author":"Macedo","year":"2020","journal-title":"J ImmunoTherapy Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01897-x","article-title":"Intratumoral oncolytic herpes virus G47\u0394 for residual or recurrent glioblastoma: a phase 2 trial","volume":"28","author":"Todo","year":"2022","journal-title":"Nat Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-016-5286-0","article-title":"Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trial","volume":"23","author":"Andtbacka","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.12.007","article-title":"Combination with oxaliplatin improves abscopal effect of oncolytic virotherapy through reorganization of intratumoral macrophages","volume":"33","author":"Tomita","year":"2025","journal-title":"Mol Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1112960","article-title":"Correlative analysis from a phase I clinical trial of intrapleural administration of oncolytic vaccinia virus (Olvi-vec) in patients with Malignant pleural mesothelioma","volume":"14","author":"Chintala","year":"2023","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2017.07.005","article-title":"An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results","volume":"36","author":"Packiam","year":"2018","journal-title":"Urol Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03025-3","article-title":"Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial","volume":"30","author":"Li","year":"2024","journal-title":"Nat Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.1007","article-title":"Clinical activity of olvimulogene nanivacirepvec-Primed immunochemotherapy in heavily pretreated patients with platinum-Resistant or platinum-Refractory ovarian cancer: the nonrandomized phase 2 VIRO-15 clinical trial","volume":"9","author":"Holloway","year":"2023","journal-title":"JAMA Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201807-1415ST","article-title":"Management of Malignant pleural effusions. An official ATS\/STS\/STR clinical practice guideline","volume":"198","author":"Feller-Kopman","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12890-015-0025-z","article-title":"Important prognostic factors for survival in patients with Malignant pleural effusion","volume":"15","author":"Zamboni","year":"2015","journal-title":"BMC Pulm Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2022.04.017","article-title":"Malignant pleural effusion: presentation, diagnosis, and management","volume":"135","author":"Gayen","year":"2022","journal-title":"Am J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/resp.12496","article-title":"Clinical features and survival of lung cancer patients with pleural effusions","volume":"20","author":"Porcel","year":"2015","journal-title":"Respirology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1800349","DOI":"10.1183\/13993003.00349-2018","article-title":"ERS\/EACTS statement on the management of Malignant pleural effusions","volume":"52","author":"Bibby","year":"2018","journal-title":"Eur Respir J"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.12.128","article-title":"Frequent homozygous deletions of type I interferon genes in pleural mesothelioma confer sensitivity to oncolytic measles virus","volume":"15","author":"Delaunay","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009062","article-title":"Treatment with oncolytic vaccinia virus infects tumor-infiltrating regulatory and exhausted T cells","volume":"12","author":"DePeaux","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1490414","article-title":"Neutrophils in oncolytic virus immunotherapy","volume":"15","author":"Zhou","year":"2024","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-19-0789","article-title":"Chemotherapeutic tumor microparticles elicit a neutrophil response targeting Malignant pleural effusions","volume":"8","author":"Xu","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat Rev Drug Discovery"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2017.11.006","article-title":"Antitumor benefits of antiviral immunity: an underappreciated aspect of oncolytic virotherapies","volume":"39","author":"Gujar","year":"2018","journal-title":"Trends Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12943-020-01275-6","article-title":"Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy","volume":"19","author":"Zhang","year":"2020","journal-title":"Mol Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.2015.1115725","article-title":"Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy","volume":"15","author":"Harrington","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1172\/jci98047","article-title":"PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy","volume":"128","author":"Zamarin","year":"2018","journal-title":"J Clin Invest"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e28518","DOI":"10.4161\/onci.28518","article-title":"Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death","volume":"3","author":"Golden","year":"2014","journal-title":"Oncoimmunology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-006-0225-8","article-title":"Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients","volume":"56","author":"Ghiringhelli","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-09-3690","article-title":"5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity","volume":"70","author":"Vincent","year":"2010","journal-title":"Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2024.110093","article-title":"VP5 protein of oncolytic herpes simplex virus type 2 induces apoptosis in A549 cells through TP53I3 protein","volume":"595","author":"Wang","year":"2024","journal-title":"Virology"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00475","article-title":"Delivery and biosafety of oncolytic virotherapy","volume":"10","author":"Li","year":"2020","journal-title":"Front Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-09-3567","article-title":"Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients","volume":"70","author":"Cerullo","year":"2010","journal-title":"Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12041016","article-title":"Diagnosis and management of Malignant pleural effusion: A decade in review","volume":"12","author":"Jacobs","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.09.003","article-title":"Survival in patients with Malignant pleural effusion undergoing talc pleurodesis","volume":"137","author":"Hassan","year":"2019","journal-title":"Lung Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.17426","article-title":"Effect of an indwelling pleural catheter vs talc pleurodesis on hospitalization days in patients with Malignant pleural effusion: the AMPLE randomized clinical trial","volume":"318","author":"Thomas","year":"2017","journal-title":"Jama"},{"key":"B40","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.lungcan.2017.01.019","article-title":"A randomized controlled trial comparing indwelling pleural catheters with talc pleurodesis (NVALT-14)","volume":"108","author":"Boshuizen","year":"2017","journal-title":"Lung Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2014.02.027","article-title":"A propensity-matched comparison of pleurodesis or tunneled pleural catheter for heart failure patients with recurrent pleural effusion","volume":"97","author":"Freeman","year":"2014","journal-title":"Ann Thorac Surg"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010529.pub3","article-title":"Interventions for the management of Malignant pleural effusions: an updated network meta-analysis","volume":"4","author":"Dipper","year":"2021","journal-title":"Eur Respir Rev"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2010.136994","article-title":"Management of a Malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010","author":"Roberts","year":"2010","journal-title":"Thorax"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-2366","article-title":"Symptom management in patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"143","author":"Simoff","year":"2013","journal-title":"Chest"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.5535","article-title":"Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with Malignant pleural effusion: the TIME2 randomized controlled trial","volume":"307","author":"Davies","year":"2012","journal-title":"Jama"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1097\/lbr.0000000000000707","article-title":"AABIP evidence-informed guidelines and expert panel report for the management of indwelling pleural catheters","volume":"27","author":"Miller","year":"2020","journal-title":"J Bronchology Interv Pulmonol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.11.031","article-title":"The frequency, risk factors, and management of complications from pleural procedures","volume":"161","author":"Sundaralingam","year":"2022","journal-title":"Chest"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-3103","article-title":"Clinical outcomes of indwelling pleural catheter-related pleural infections: an international multicenter study","volume":"144","author":"Fysh","year":"2013","journal-title":"Chest"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100424","article-title":"Osimertinib and bevacizumab cotreatment for untreated EGFR-mutated NSCLC with Malignant pleural or pericardial effusion (SPIRAL II): A single-arm, open-label, phase 2 clinical trial","volume":"3","author":"Hibino","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-019-00882-5","article-title":"Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study","volume":"38","author":"Kawachi","year":"2020","journal-title":"Invest New Drugs"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100355","article-title":"Efficacy of immune checkpoint inhibitor with or without chemotherapy for nonsquamous NSCLC with Malignant pleural effusion: A retrospective multicenter cohort study","volume":"3","author":"Kawachi","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.1084","article-title":"Safety interim analysis (SIA) of atractib: A phase 2 trial of first-line (1L) atezolizumab (A) in combination with paclitaxel (P) and bevacizumab (B) in metastatic triple-negative breast cancer (mTNBC)","volume":"40","author":"Cortes","year":"2022","journal-title":"J Clin Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.02.003","article-title":"Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer","volume":"31","author":"Adams","year":"2020","journal-title":"Ann Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-19-0851","article-title":"TBCRC023: A randomized phase II neoadjuvant trial of lapatinib plus trastuzumab without chemotherapy for 12 versus 24 weeks in patients with HER2-positive breast cancer","volume":"26","author":"Rimawi","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B58","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1186\/s12885-018-4581-5","article-title":"Thoracic injection of low-dose interleukin-2 as an adjuvant therapy improves the control of the Malignant pleural effusions: a systematic review and meta-analysis base on Chinese patients","volume":"18","author":"Han","year":"2018","journal-title":"BMC Cancer"},{"key":"B59","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1186\/s12885-016-2935-4","article-title":"Thoracic perfusion of recombinant human endostatin (Endostar) combined with chemotherapeutic agents versus chemotherapeutic agents alone for treating Malignant pleural effusions: a systematic evaluation and meta-analysis","volume":"16","author":"Biaoxue","year":"2016","journal-title":"BMC Cancer"},{"key":"B60","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/1759-7714.13238","article-title":"A randomized clinical study to compare intrapleural infusion with intravenous infusion of bevacizumab in the management of Malignant pleural effusion in patients with non-small-cell lung cancer","volume":"11","author":"Nie","year":"2020","journal-title":"Thorac Cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-1035","article-title":"A phase II study of bevacizumab in non-squamous, non-small-cell lung cancer patients with Malignant pleural effusion","volume":"18","author":"Di","year":"2022","journal-title":"Future Oncol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s13019-024-02751-6","article-title":"Efficacy and safety of intrapleural perfusion with hyperthermic chemotherapy for Malignant pleural effusion: a meta-analysis","volume":"19","author":"Pan","year":"2024","journal-title":"J Cardiothorac Surg"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.4891.4891","article-title":"Malignant pleural effusion and advanced stage low-Grade non-Hodgkin\u2019s lymphoma successfully treated with intrapleural instillation of rituximab","volume":"120","author":"Islam","year":"2012","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-013-0676-7","article-title":"Phase2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with Malignant pleural effusion","volume":"30","author":"Tamiya","year":"2013","journal-title":"Med Oncol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/1759-7714.12582","article-title":"Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma-induced Malignant pleural effusion","volume":"9","author":"Tao","year":"2018","journal-title":"Thorac Cancer"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-021-01076-8","article-title":"Phase 2 study of bevacizumab plus carboplatin\/nab-paclitaxel followed by bevacizumab plus nab-paclitaxel for non-squamous non-small cell lung cancer with Malignant pleural effusion","volume":"39","author":"Tamiya","year":"2021","journal-title":"Invest New Drugs"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.63.5995","article-title":"Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction","volume":"34","author":"Li","year":"2016","journal-title":"J Clin Oncol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3039","article-title":"Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial","volume":"4","author":"Han","year":"2018","journal-title":"JAMA Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14176","article-title":"Effectiveness of anlotinib in patients with small-cell lung cancer and pleural effusion: Subgroup analysis from a randomized, multicenter, phase II study","volume":"12","author":"Liu","year":"2021","journal-title":"Thorac Cancer"},{"key":"B70","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.1136\/thorax-2022-219784","article-title":"British Thoracic Society Guideline for pleural disease","volume":"78","author":"Roberts","year":"2023","journal-title":"Thorax"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1111\/resp.13812","article-title":"Role of early definitive management for newly diagnosed Malignant pleural effusion related to lung cancer","volume":"25","author":"Chiang","year":"2020","journal-title":"Respirology"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.75.8219","article-title":"Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent Malignant glioma","volume":"36","author":"Lang","year":"2018","journal-title":"J Clin Oncol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"e1004035","DOI":"10.1371\/journal.ppat.1004035","article-title":"IL-1\u03b1 and complement cooperate in triggering local neutrophilic inflammation in response to adenovirus and eliminating virus-containing cells","volume":"10","author":"Di Paolo","year":"2014","journal-title":"PloS Pathog"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3089","article-title":"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer","volume":"19","author":"Heo","year":"2013","journal-title":"Nat Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-05-1059","article-title":"CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor\u2013armed oncolytic adenovirus for the treatment of bladder cancer","volume":"12","author":"Ramesh","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1701021","article-title":"Critical interactions between immunogenic cancer cell death, oncolytic viruses, and the immune system define the rational design of combination immunotherapies","volume":"200","author":"van Vloten","year":"2018","journal-title":"J\u00a0Immunol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1097\/xcs.0000000000000964","article-title":"Using oncolytic virus to retask CD19-chimeric antigen receptor T cells for treatment of pancreatic cancer: toward a universal chimeric antigen receptor T-cell strategy for solid tumor","volume":"238","author":"Chen","year":"2024","journal-title":"J\u00a0Am Coll Surg"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114867","article-title":"Developing enhanced immunotherapy using NKG2A knockout human pluripotent stem cell-derived NK cells","volume":"43","author":"Qin","year":"2024","journal-title":"Cell Rep"},{"key":"B80","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.trsl.2021.10.006","article-title":"NK cell tumor therapy modulated by UV-inactivated oncolytic herpes simplex virus type 2 and checkpoint inhibitors","volume":"240","author":"Wang","year":"2022","journal-title":"Transl Res"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-19-2095","article-title":"The NKG2A-HLA-E axis as a novel checkpoint in the tumor microenvironment","volume":"26","author":"Borst","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14754","article-title":"Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy","volume":"8","author":"Liu","year":"2017","journal-title":"Nat Commun"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3390\/v7122953","article-title":"Dendritic cells in oncolytic virus-Based anti-Cancer therapy","volume":"7","author":"Kim","year":"2015","journal-title":"Viruses"},{"key":"B84","doi-asserted-by":"publisher","first-page":"9933","DOI":"10.1038\/s41467-024-54111-6","article-title":"VSV(\u0394M51) drives CD8(+) T cell-mediated tumour regression through infection of both cancer and non-cancer cells","volume":"15","author":"Rajwani","year":"2024","journal-title":"Nat Commun"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101229","article-title":"Oncolytic virus M1 functions as a bifunctional checkpoint inhibitor to enhance the antitumor activity of DC vaccine","volume":"4","author":"Dan","year":"2023","journal-title":"Cell Rep Med"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2019.1591875","article-title":"Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma","volume":"8","author":"Bommareddy","year":"2019","journal-title":"Oncoimmunology"},{"key":"B87","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41392-024-01824-1","article-title":"Combination therapy with oncolytic virus and T cells or mRNA vaccine amplifies antitumor effects","volume":"9","author":"Fu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B88","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1186\/s12916-022-02574-z","article-title":"SIRP\u03b1 antibody combined with oncolytic virus OH2 protects against tumours by activating innate immunity and reprogramming the tumour immune microenvironment","volume":"20","author":"Kong","year":"2022","journal-title":"BMC Med"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.15101","article-title":"Effectiveness and safety of human type 5 recombinant adenovirus (H101) in Malignant tumor with Malignant pleural effusion and ascites: A multicenter, observational, real-world study","volume":"14","author":"Wang","year":"2023","journal-title":"Thorac Cancer"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.02.015","article-title":"Phase I study of intrapleural gene-mediated cytotoxic immunotherapy in patients with Malignant pleural effusion","volume":"26","author":"Aggarwal","year":"2018","journal-title":"Mol Ther"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e20536","article-title":"Granular analysis of individual immune-related gene expression in a randomized phase I\/II study of the oncolytic adenovirus, ONCOS-102, in combination with pemetrexed\/cisplatin (P\/C) in patients (pts) with unresectable Malignant pleural mesothelioma (MPM)","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.07.005","article-title":"Oncolytic herpesvirus therapy for mesothelioma \u2013 A phase I\/IIa trial of intrapleural administration of HSV1716","volume":"150","author":"Danson","year":"2020","journal-title":"Lung Cancer"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2018.1442169","article-title":"Heating it up: Oncolytic viruses make tumors \u2018hot\u2019 and suitable for checkpoint blockade immunotherapies","volume":"7","author":"Gujar","year":"2018","journal-title":"Oncoimmunology"},{"key":"B94","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ebiom.2018.04.020","article-title":"Lighting a fire in the tumor microenvironment using oncolytic immunotherapy","volume":"31","author":"Achard","year":"2018","journal-title":"EBioMedicine"},{"key":"B95","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.immuni.2013.07.005","article-title":"Deciphering and reversing tumor immune suppression","volume":"39","author":"Motz","year":"2013","journal-title":"Immunity"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.16","article-title":"Vaccines for established cancer: overcoming the challenges posed by immune evasion","volume":"16","author":"van der Burg","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw168","article-title":"Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy","volume":"27","author":"Pitt","year":"2016","journal-title":"Ann Oncol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1201449","article-title":"Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer","volume":"190","author":"Yu","year":"2013","journal-title":"J Immunol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/s1471-4906(03)00132-7","article-title":"L-arginine metabolism in myeloid cells controls T-lymphocyte functions","volume":"24","author":"Bronte","year":"2003","journal-title":"Trends Immunol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.cytogfr.2018.03.006","article-title":"Armed oncolytic viruses: A kick-start for anti-tumor immunity","volume":"41","author":"de Graaf","year":"2018","journal-title":"Cytokine Growth Factor Rev"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-12-103","article-title":"Oncolytic viruses as therapeutic cancer vaccines","volume":"12","author":"Bartlett","year":"2013","journal-title":"Mol Cancer"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00074","article-title":"Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity","volume":"4","author":"Guo","year":"2014","journal-title":"Front Oncol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-0716-3291-8_19","article-title":"Intravesical infusion of oncolytic virus CG0070 in the treatment of bladder cancer","volume":"2684","author":"Grandi","year":"2023","journal-title":"Methods Mol Biol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2022.343","article-title":"Neoadjuvant nivolumab plus gemcitabine\/cisplatin chemotherapy in muscle-invasive urothelial carcinoma of the bladder","volume":"55","author":"Kim","year":"2023","journal-title":"Cancer Res Treat"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01846-z","article-title":"Nadofaragene firadenovec: first approval","volume":"83","author":"Lee","year":"2023","journal-title":"Drugs"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-07-0146","article-title":"Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus","volume":"67","author":"Zhang","year":"2007","journal-title":"Cancer Res"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-451","article-title":"Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68","volume":"11","author":"Ascierto","year":"2011","journal-title":"BMC Cancer"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-18-0244","article-title":"Phase I study of oncolytic vaccinia virus GL-ONC1 in patients with peritoneal carcinomatosis","volume":"24","author":"Lauer","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006374","article-title":"OncoVEX(mGM-CSF)expands tumor antigen-specific CD8+ T-cell response in preclinical models","volume":"11","author":"Estrada","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-08717-5","article-title":"Oncolytic virus VG161 in refractory hepatocellular carcinoma","author":"Shen","year":"2025","journal-title":"Nature"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-021-11059-x","article-title":"Harnessing the potential of combination immunotherapy and oncolytic virotherapy for solid tumors","volume":"29","author":"Cohen","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1412896","article-title":"Talimogene laherparepvec: First in class oncolytic virotherapy","volume":"14","author":"Conry","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"B114","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s40425-019-0623-z","article-title":"Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma","volume":"7","author":"Andtbacka","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.73.7379","article-title":"Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma","volume":"36","author":"Chesney","year":"2018","journal-title":"J Clin Oncol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2147\/ov.S56322","article-title":"Applications of coxsackievirus A21 in oncology","volume":"3","author":"Bradley","year":"2014","journal-title":"Oncolytic Virother"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.03246","article-title":"Clinical responses of oncolytic coxsackievirus A21 (V937) in patients with unresectable melanoma","volume":"39","author":"Andtbacka","year":"2021","journal-title":"J Clin Oncol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.9553","article-title":"Updated results from the skin cancer cohorts from an ongoing phase 1\/2 multicohort study of RP1, an enhanced potency oncolytic HSV, combined with nivolumab (IGNYTE)","volume":"40","author":"Milhem","year":"2022","journal-title":"J Clin Oncol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"e1264563","DOI":"10.1080\/2162402x.2016.1264563","article-title":"Adaptive T cell responses induced by oncolytic Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapy","volume":"6","author":"Ren","year":"2017","journal-title":"Oncoimmunology"},{"key":"B120","doi-asserted-by":"publisher","first-page":"e004307","DOI":"10.1136\/jitc-2021-004307","article-title":"OrienX010, an oncolytic virus, in patients with unresectable stage IIIC-IV melanoma: a phase Ib study","volume":"10","author":"Cui","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00149","article-title":"Genomic signature of the natural oncolytic herpes simplex virus HF10 and its therapeutic role in preclinical and clinical trials","volume":"7","author":"Eissa","year":"2017","journal-title":"Front Oncol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.9543","article-title":"Preliminary results from phase II study of combination treatment with HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab in patients with stage IIIb, IIIc, or IV unresectable or metastatic melanoma","volume":"34","author":"Andtbacka","year":"2016","journal-title":"J Clin Oncol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.9115","article-title":"Stereotactic body radiation therapy and in situ oncolytic virus therapy followed by immunotherapy in metastatic non-small cell lung cancer","volume":"39","author":"Guerrero","year":"2021","journal-title":"J Clin Oncol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-22-0927","article-title":"Combination IFN\u03b2 and membrane-stable CD40L maximize tumor dendritic cell activation and lymph node trafficking to elicit systemic T-cell immunity","volume":"11","author":"Zheng","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2024.101056","article-title":"Oncolytic adenovirus MEM-288 encoding membrane-stable CD40L and IFN\u03b2 induces an anti-tumor immune response in high grade serous ovarian cancer","volume":"57","author":"Peters","year":"2024","journal-title":"Neoplasia"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.2569","article-title":"A phase 1 first-in-human study of interferon beta (IFN\u03b2) and membrane-stable CD40L expressing oncolytic virus (MEM-288) in solid tumors including non\u2013small-cell lung cancer (NSCLC)","volume":"41","author":"Saltos","year":"2023","journal-title":"J Clin Oncol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"e003368","DOI":"10.1136\/jitc-2021-003368","article-title":"Systemic high-dose dexamethasone treatment may modulate the efficacy of intratumoral viral oncolytic immunotherapy in glioblastoma models","volume":"10","author":"Koch","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.8634","article-title":"Overall survival after treatment with CAN-2409 plus valacyclovir in combination with continued ICI in patients with stage III\/IV NSCLC with an inadequate response to ICI","volume":"42","author":"Aggarwal","year":"2024","journal-title":"J Clin Oncol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.2174\/1568009618666171129221503","article-title":"Oncorine, the world first oncolytic virus medicine and its update in China","volume":"18","author":"Liang","year":"2018","journal-title":"Curr Cancer Drug Targets"},{"key":"B130","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1186\/s12935-021-02024-5","article-title":"A review on the advances and challenges of immunotherapy for head and neck cancer","volume":"21","author":"Cheng","year":"2021","journal-title":"Cancer Cell Int"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.752504","article-title":"A recombinant human adenovirus type 5 (H101) combined with chemotherapy for advanced gastric carcinoma: A retrospective cohort study","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"e93103","DOI":"10.1371\/journal.pone.0093103","article-title":"A novel oncolytic herpes simplex virus type 2 has potent anti-tumor activity","volume":"9","author":"Zhao","year":"2014","journal-title":"PloS One"},{"key":"B133","doi-asserted-by":"publisher","first-page":"e002224","DOI":"10.1136\/jitc-2020-002224","article-title":"Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I\/II clinical trial","volume":"9","author":"Zhang","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B134","doi-asserted-by":"publisher","first-page":"e28108","DOI":"10.1002\/jmv.28108","article-title":"VG161 activates systemic antitumor immunity in pancreatic cancer models as a novel oncolytic herpesvirus expressing multiple immunomodulatory transgenes","volume":"95","author":"Shen","year":"2023","journal-title":"J Med Virol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.4105","article-title":"Clinical outcomes from a phase I clinical trial of a novel oncolytic virus VG161 in patients with hepatocellular carcinoma (HCC) refractory after 2 prior lines of therapy including checkpoint inhibitors (CPI)","volume":"42","author":"Shen","year":"2024","journal-title":"J Clin Oncol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2147\/ov.S51321","article-title":"Reovirus in cancer therapy: an evidence-based review","volume":"3","author":"Clements","year":"2014","journal-title":"Oncolytic Virother"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.3390\/v15030698","article-title":"Viral vectors in gene therapy: where do we stand in 2023","volume":"15","author":"Lundstrom","year":"2023","journal-title":"Viruses"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.1012","article-title":"BRACELET-1 (PrE0113): Inducing an inflammatory phenotype in metastatic HR+\/HER2- breast cancer with the oncolytic reovirus pelareorep in combination with paclitaxel and avelumab","volume":"41","author":"Clark","year":"2023","journal-title":"J Clin Oncol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02210-0","article-title":"Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial","volume":"29","author":"Soliman","year":"2023","journal-title":"Nat Med"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.101136398","article-title":"Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing","volume":"98","author":"Todo","year":"2001","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B141","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12865-018-0281-9","article-title":"Oncolytic herpes simplex virus and immunotherapy","volume":"19","author":"Ma","year":"2018","journal-title":"BMC Immunol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1358\/dof.2010.35.3.1470166","article-title":"ONCOLYTIC HERPES SIMPLEX VIRUS 1 (HSV-1) VECTORS: INCREASING TREATMENT EFFICACY AND RANGE THROUGH STRATEGIC VIRUS DESIGN","volume":"35","author":"Carson","year":"2010","journal-title":"Drugs Future"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02347-y","article-title":"Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1\/2 trial","volume":"29","author":"Nassiri","year":"2023","journal-title":"Nat\u00a0Med"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2020.03.028","article-title":"Preclinical toxicology of rQNestin34.5v.2: an oncolytic herpes virus with transcriptional regulation of the ICP34.5 neurovirulence gene","volume":"17","author":"Chiocca","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06623-2","article-title":"Clinical trial links oncolytic immunoactivation to survival in glioblastoma","volume":"623","author":"Ling","year":"2023","journal-title":"Nature"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.12.6803","article-title":"Intergeneric poliovirus recombinants for the treatment of Malignant glioma","volume":"97","author":"Gromeier","year":"2000","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002203","article-title":"Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma","volume":"9","author":"Beasley","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.101875","article-title":"Elucidating cellular response to treatment with viral immunotherapies in pediatric high-grade glioma and medulloblastoma","volume":"40","author":"Thompson","year":"2024","journal-title":"Transl Oncol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716435","article-title":"Recurrent glioblastoma treated with recombinant poliovirus","volume":"379","author":"Desjardins","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.249","article-title":"Maraba virus as a potent oncolytic vaccine vector","volume":"22","author":"Pol","year":"2014","journal-title":"Mol Ther"},{"key":"B151","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.biologicals.2018.06.002","article-title":"Detection of bovine viral diarrhoea virus nucleic acid, but not infectious virus, in bovine serum used for human vaccine manufacture","volume":"55","author":"Laassri","year":"2018","journal-title":"Biologicals"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.7326\/m23-0385","article-title":"Performance of rapid antigen tests to detect symptomatic and asymptomatic SARS-coV-2 infection: A prospective cohort study","volume":"176","author":"Soni","year":"2023","journal-title":"Ann Intern Med"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.3390\/v15010178","article-title":"Development and preliminary application of a droplet digital PCR assay for quantifying the oncolytic herpes simplex virus type 1 in the clinical-grade production","volume":"15","author":"Guo","year":"2023","journal-title":"Viruses"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.01.035","article-title":"Chimeric oncolytic adenovirus evades neutralizing antibodies from human patients and exhibits enhanced anti-glioma efficacy in immunized mice","volume":"32","author":"Shin","year":"2024","journal-title":"Mol Ther"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252413697","article-title":"Microbubble-protected oncolytic virotherapy targeted by sonoporation induces tumor necrosis and T-lymphocyte infiltration in humanized mice bearing triple-negative breast cancer","volume":"25","author":"Sitta","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110969","article-title":"Inactivation of the DNA-sensing pathway facilitates oncolytic herpes simplex virus inhibition of pancreatic ductal adenocarcinoma growth","volume":"124","author":"Zhang","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004762","article-title":"Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade","volume":"10","author":"Ju","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq048","article-title":"Drake CG Assessing oncologic benefit in clinical trials of immunotherapy agents","volume":"21","author":"Hales","year":"2010","journal-title":"Ann Oncol"},{"key":"B159","doi-asserted-by":"publisher","first-page":"e003302","DOI":"10.1136\/jitc-2021-003302","article-title":"Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival","volume":"10","author":"Manitz","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B160","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2021.08.006","article-title":"Enzymatically produced piggyBac transposon vectors for efficient non-viral manufacturing of CD19-specific CAR T cells","volume":"23","author":"Ka\u0161t\u00e1nkov\u00e1","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2021.02.010","article-title":"Analytical methods for process and product characterization of recombinant adeno-associated virus-based gene therapies","volume":"20","author":"Gimpel","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.3390\/v8060167","article-title":"Development of an oncolytic adenovirus with enhanced spread ability through repeated UV irradiation and cancer selection","volume":"8","author":"Wechman","year":"2016","journal-title":"Viruses"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2024.1505338","article-title":"Repeated harvest enables efficient production of VSV-GP","volume":"12","author":"Habisch","year":"2024","journal-title":"Front Bioeng Biotechnol"},{"key":"B165","doi-asserted-by":"publisher","first-page":"16002","DOI":"10.1038\/mtm.2016.2","article-title":"Manufacturing of recombinant adeno-associated viral vectors for clinical trials","volume":"3","author":"Cl\u00e9ment","year":"2016","journal-title":"Mol Ther - Methods Clin Dev"},{"key":"B166","doi-asserted-by":"publisher","first-page":"13601","DOI":"10.1038\/s41598-019-49624-w","article-title":"Production of adeno-associated virus vectors for in vitro and in vivo applications","volume":"9","author":"Kimura","year":"2019","journal-title":"Sci Rep"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-020-0192-9","article-title":"Use of cell fusion proteins to enhance adenoviral vector efficacy as an anti-cancer therapeutic","volume":"28","author":"Del Papa","year":"2021","journal-title":"Cancer Gene Ther"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24043681","article-title":"The dilemma of HSV-1 oncolytic virus delivery: the method choice and hurdles","volume":"24","author":"Tang","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B169","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.cell.2024.12.010","article-title":"Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients","volume":"188","author":"Zhong","year":"2025","journal-title":"Cell"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105094","article-title":"Multidirectional strategies for targeted delivery of oncolytic viruses by tumor infiltrating immune cells","volume":"161","author":"Osali","year":"2020","journal-title":"Pharmacol Res"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1002\/dc.25201","article-title":"Role of cytoblock on pleural effusion for diagnosis of Malignant disease","volume":"51","author":"Shahini","year":"2023","journal-title":"Diagn Cytopathol"},{"key":"B172","doi-asserted-by":"publisher","first-page":"e27549","DOI":"10.7759\/cureus.27549","article-title":"Intrapleural fibrinolytic therapy with alteplase for the management of multiloculated Malignant pleural effusion: A case series","volume":"14","author":"Nemet","year":"2022","journal-title":"Cureus"},{"key":"B173","doi-asserted-by":"publisher","first-page":"e2300244","DOI":"10.1002\/biot.202300244","article-title":"Development, optimization, and scale-up of suspension Vero cell culture process for high titer production of oncolytic herpes simplex virus-1","volume":"19","author":"Shen","year":"2024","journal-title":"Biotechnol J"},{"key":"B174","doi-asserted-by":"publisher","first-page":"59","DOI":"10.32607\/actanaturae.27314","article-title":"A method for the production of recombinant VSVs with confirmation of biological activity","volume":"16","author":"Moroz","year":"2024","journal-title":"Acta Naturae"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2021.105726","article-title":"Optimization of a GDNF production method based on Semliki Forest virus vector","volume":"159","author":"Torres-Ortega","year":"2021","journal-title":"Eur J Pharm Sci"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1002\/bit.28530","article-title":"Characterization of a quail suspension cell line for production of a fusogenic oncolytic virus","volume":"120","author":"G\u00f6bel","year":"2023","journal-title":"Biotechnol Bioeng"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2023.1193454","article-title":"Glutathione affinity chromatography for the scalable purification of an oncolytic virus immunotherapy from microcarrier cell culture","volume":"11","author":"Swartz","year":"2023","journal-title":"Front Bioeng Biotechnol"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2021.461924","article-title":"Comparative evaluation of integrated purification pathways for bacterial modular polyomavirus major capsid protein VP1 to produce virus-like particles using high throughput process technologies","volume":"1639","author":"Gerstweiler","year":"2021","journal-title":"J Chromatogr A"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2022.06.013","article-title":"Binding of Coxsackievirus A21 procapsids to immobilized glutathione depends on cell culture conditions during infection","volume":"573","author":"Swartz","year":"2022","journal-title":"Virology"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.992069","article-title":"Single-step rapid chromatographic purification and characterization of clinical stage oncolytic VSV-GP","volume":"10","author":"Gautam","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1002\/bit.27779","article-title":"Oncolytic virus purification with periodic counter-current chromatography","volume":"118","author":"Mendes","year":"2021","journal-title":"Biotechnol Bioeng"},{"key":"B182","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.omtm.2023.07.010","article-title":"Combined clarification and affinity capture using magnetic resin enables efficient separation of rAAV5 from cell lysate","volume":"30","author":"Turco","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1002\/bit.28419","article-title":"Downstream process design for Gag HIV-1 based virus-like particles","volume":"120","author":"Lorenzo","year":"2023","journal-title":"Biotechnol Bioeng"},{"key":"B184","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1186\/s12967-023-04360-8","article-title":"Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy","volume":"21","author":"Wang","year":"2023","journal-title":"J Transl Med"},{"key":"B185","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s40780-024-00388-0","article-title":"Safety of talimogene laherparepvec: a real-world retrospective pharmacovigilance study based on FDA Adverse Event Reporting System (FAERS)","volume":"10","author":"Hong","year":"2024","journal-title":"J Pharm Health Care Sci"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2018.170","article-title":"Preclinical safety evaluation of oncolytic herpes simplex virus type 2","volume":"30","author":"Wang","year":"2019","journal-title":"Hum Gene Ther"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110975","article-title":"Preclinical safety assessment of an oncolytic herpes simplex virus type 2 expressed PD-L1\/CD3 bispecific antibody","volume":"124","author":"Wang","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B188","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13046-024-03011-0","article-title":"Oncolytic adenovirus encoding apolipoprotein A1 suppresses metastasis of triple-negative breast cancer in mice","volume":"43","author":"Dong","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"B189","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.omto.2017.07.001","article-title":"Efficacy and safety of doubly-Regulated vaccinia virus in a mouse xenograft model of multiple myeloma","volume":"6","author":"Futami","year":"2017","journal-title":"Mol Ther Oncolytics"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aam7996","article-title":"Targeting VCP enhances anticancer activity of oncolytic virus M1 in hepatocellular carcinoma","volume":"9","author":"Zhang","year":"2017","journal-title":"Sci Transl Med"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006408","article-title":"Adaptation of transgene mRNA translation boosts the anticancer efficacy of oncolytic HSV1","volume":"11","author":"Hoang","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B192","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/s13046-024-03219-0","article-title":"Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors","volume":"43","author":"Jirovec","year":"2024","journal-title":"J\u00a0Exp Clin Cancer Res"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2021.04.078","article-title":"An oncolytic vaccinia virus armed with anti-human-PD-1 antibody and anti-human-4-1BB antibody double genes for cancer-targeted therapy","volume":"559","author":"Shi","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1039\/d2bm00200k","article-title":"Bioreducible polymer-mediated delivery of oncolytic adenovirus can attenuate antiviral immune response and concurrently enhance the induction of antitumor immune response to effectively prevent metastasis","volume":"10","author":"Kasala","year":"2022","journal-title":"Biomater Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1570698\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T05:23:10Z","timestamp":1745558590000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1570698\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":194,"alternative-id":["10.3389\/fimmu.2025.1570698"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1570698","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,25]]},"article-number":"1570698"}}